TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy males or females between, and including, 12 and 18 years of age at the time of the first vaccination.~* Female subjects must be of non-childbearing potential.~Exclusion Criteria:~* Previous vaccination against or history of meningococcal B or C, or hepatitis A disease or exposure to meningococcal B disease within last year.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~* Family history of congenital or hereditary immunodeficiency.~* History of any neurologic disorders or seizures.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current active episode of BV (diagnosis defined as: At least 3 of the 4 Amsel criteria; Nugent score of at least 4; presence of BV-related symptoms)~* History of recurrent BV (at least 3 episodes in previous year including current episode)~* Using an effective method of contraception~Exclusion Criteria:~* Test positive for a sexually transmitted infection~* Presence of genital Herpes Simplex Virus (HSV) lesions or Human Papilloma Virus (HPV) lesions requiring treatment~* Abnormal pelvic exam, including presence of other vaginal or urinary tract infections~* Pregnancy

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1% SPL7013 Gel (Type: EXPERIMENTAL): Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
- Placebo Gel (Type: PLACEBO_COMPARATOR): Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven renal cell carcinoma with metastases.~* Evidence of unidimensionally measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST).~* Failure of 1 prior cytokine-based therapy for metastatic disease. Patients treated with IFN-á alone must have received IFN-á for at least 4 weeks.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.~* Resolution of all acute toxic effects of prior therapy or surgical procedures to grade 1.~* Adequate organ function~Exclusion Criteria:~* Prior treatment with any systemic therapy other than 1 cytokine-based therapy.~* Previous treatment on a SU011248 (sunitinib) clinical trial.~* Major surgery, radiation therapy, or systemic therapy within 4 weeks of starting the study treatment.~* Diagnosis of any second malignancy within the last 3 years, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma that has been adequately treated with no evidence of recurrent disease for 12 months.~* History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan.~* Any of the following within the 12 months prior to starting the study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.~* Ongoing cardiac dysrhythmias of grade 2, atrial fibrillation of any grade, or QTc interval \>450 msec for males or \>470 msec for females.~* Hypertension that cannot be controlled by medications (\>150/100 mmHg despite optimal medical therapy).~* Ongoing treatment with therapeutic doses of Coumadin (however, low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).~* Known human immunodeficiency virus (HIV) infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SU011248 (sunitinib) (Type: EXPERIMENTAL): Single-arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* Male or female subjects of any race, ages 18-75 inclusive~* Meets the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM 5) criteria for Bipolar I or Bipolar II Disorder or MDD~* The start of the current major depressive episode is at least 2 weeks but no more than 6 months prior to the Screening (Visit 1)~* Has at least moderate severity of illness, as measured by a rater-administered MADRS total score ≥ 24 and corresponding to a CGI S score of ≥ 4 at Screening (Visit 1) and Baseline (Visit 2)~* The patient meets the DSM-5 criteria for mixed-features specific to the Bipolar I or II diagnosis or MDD diagnosis~* Current major depressive episode is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning~* Able to provide written informed consent~Major Exclusion Criteria:~* Any female subject who is pregnant or breast-feeding~* Any subject judged to be medically inappropriate for study participation~* The patient has a significant risk for suicidal behavior~* The patient presents with a lifetime history of epilepsy, seizure or convulsion, or electroencephalogram with clinically significant abnormalities, delirium, dementia, amnestic, or other cognitive disorder or significant brain trauma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lumateperone 42mg (Type: EXPERIMENTAL): Lumateperone 42mg administered once daily in the evening
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo administered once daily in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participation in the original S/GHD/004/NOO trial or following the protocol for S/GHD/004/NOO without being randomised in the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low dose 33 mcg/kg/day (Type: EXPERIMENTAL): None
- High dose 66 mcg/kg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study in Subjects With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient~* ≥18 years of age at Visit 1~* Male or Eligible Female~* Diagnosis of asthma at least 12 weeks prior to Visit 1~* Disease reversibility~* Current anti-asthma therapy~* Appropriately signed and dated informed consent has been obtained~* Able to comply with all the study requirements~Exclusion Criteria:~* History of Life-Threatening Asthma~* No use of systemic corticosteroids for any indication within 8 weeks prior to Visit~* No concurrent diseases/abnormalities that would put the safety of the subject at risk through study participation~* Drug Allergy to β2 agonist or sympathomimetic drugs, or known or suspected sensitivity to lactose or magnesium stearate~* History of severe milk protein allergy~* Non-compliance with study medication and other study-related requirements~* No use of inhaled tobacco products within the past three months or historical use of 10 pack years or more~* Administration of prohibited medications and non-drug therapies and corresponding timeframes as outlined in the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C/E/A/B/D (Type: EXPERIMENTAL): GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD/GW642444 Dose 3 QD
- D/C/E/A/B (Type: EXPERIMENTAL): GW642444 Dose 3 QD/GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD
- A/B/C/D/E (Type: EXPERIMENTAL): placebo/GW642444 Dose 1 BD/GW642444 Dose 2 QD/GW642444 Dose 3 QD/GW642444 Dose 4 QD
- B/A/D/E/C (Type: EXPERIMENTAL): GW642444 Dose 1 BD/placebo/GW642444 Dose 3 QD/GW642444 Dose 4 QD/GW642444 Dose 2 QD
- E/D/B/C/A (Type: EXPERIMENTAL): GW642444 Dose 4 QD/GW642444 Dose 3 QD/GW642444 Dose 1 BD/GW642444 Dose 2 QD/placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥ 18 years old~2. Diagnosis of NMO or NMO spectrum disorder~3. Clinical evidence of at least 2 relapses in last 12 months or 3 relapses in the last 24 months~4. Able and willing to give written informed consent and comply with the requirements of the study protocol.~5. EDSS \<= 7.5 (8 in special circumstances)~6. Men and women of reproductive potential must agree to use a highly effective method of birth control from screening to 6 months after final dose of the investigational product.~Exclusion Criteria:~1. Current evidence or known history of clinically significant infection (Herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus,human immunodeficiency virus, Hepatitis viruses, Syphilis, etc)~2. Pregnant, breastfeeding, or child-bearing potential during the course of the study~3. Patients will not participate in any other clinical therapeutic study or will not have participated in any other experimental treatment study within 30 days of screening~4. Participation in another interventional trial within the last 3 months~5. Heart or kidney insufficiency~6. Tumor disease currently or within last 5 years~7. Clinically relevant liver, kidney or bone marrow function disorder~8. Intolerance of azathioprine or previous relapses on azathioprine treatment~9. Receipt of rituximab or any experimental B-cell depleting agent within 6 months prior screening and B-cells below the lower limit of normal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): Tocilizumab Injection (ACTEMRA®) , a IL-6 receptor blockade
- Azathioprine (Type: ACTIVE_COMPARATOR): Imuran

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has HbA1c \>7.0% and \<=10.5%~* Has a body mass index (BMI) \>=25 kg/m2 and \<=45 kg/m2~* Has received insulin glargine for 3 months prior to study start and has been on a stable dose for 1 month prior to study start~* If taking oral antidiabetic agents, has been on a stable dose for at least 2 months~Exclusion Criteria:~* Has been previously treated with Symlin/pramlintide (or has participated in a Symlin/pramlintide clinical study)~* Has received any investigational drug within 1 month of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pramlintide (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-75 years of age;~* type 2 diabetes treated with a stable dose of metformin and sulphonylurea for at least 12 weeks;~* C-peptide (fasting) \>=1.0ng/mL;~* HbA1c \>=7.0% and \<=10.0% at screening;~* BMI \>=25 (\>23 for Asians) and \<=45kg/m2 at screening;~* stable weight +-5% for at least 12 weeks prior to screening.~Exclusion Criteria:~* history of type 1 diabetes mellitus or acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma in the previous 6 months;~* evidence of clinically significant diabetic complications;~* symptomatic poorly controlled diabetes;~* clinically symptomatic gastrointestinal disease;~* myocardial infarction, coronary artery bypass surgery, post-transplantation cardiomyopathy or stroke within the previous 6 months;~* known hemoglobinopathy or chronic anemia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- insulin glargine (Type: ACTIVE_COMPARATOR): insulin glargine starting dose 10 IU daily in addition to continued prestudy metformin treatment
- taspoglutide 10 mg (Type: EXPERIMENTAL): taspoglutide 10 mg once weekly in addition to continued prestudy metformin treatment
- taspoglutide 10 mg/20 mg (Type: EXPERIMENTAL): taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued prestudy metformin treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females ≥ 18 years of age with coronary artery disease with low, intermediate or high-risk coronary anatomy, which is considered suitable for PCI with stent placement.~2. Subjects who have provided written informed consent prior to initiation of any study-related procedures, prior to receiving any pre-procedural sedation and who agree to comply with all protocol-specified procedures.~Exclusion Criteria:~1. Women who are pregnant. Women of childbearing potential must have a negative pregnancy test (urine or serum HCG) within 7 days prior to randomization; as close to randomization as possible, within 24 hours preferred.~2. Allergy or intolerance to aspirin, or both clopidogrel and ticlopidine~3. Subjects with a contraindication to anticoagulation and/or increased bleeding risk:~   * Past or present bleeding disorder including a history of the following within 1 month prior to randomization: clinically relevant gastrointestinal bleeding, gross (visible) hematuria,~  * Planned major surgery including CABG after or within 1 month prior to randomization.~  * Any subject with a known coagulopathy, platelet disorder, or history of thrombocytopenia.~4. Subjects with a history of cancer (limiting survival) not known to be disease free, with the exception of basal cell carcinoma of the skin.~5. History of clinically important, recent or ongoing alcohol abuse or other drug abuse.~6. Known platelet count \<100,000/mm3 (\<100 x 109/L).~7. Subjects who is unable to give informed consent and assurance for complete contact through 2 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): treatment with Aspirin and clopidogrel for 24 months after coronary intervention with stents. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent.
- 2 (Type: ACTIVE_COMPARATOR): Treatment with aspirin and clopidogrel for minimum 1 or 6 month(s) after BMS or DES implantation, respectively. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis NSCLC (Stage IIIA, IIIB, or IV), not amenable to curative surgery or radiotherapy~* At least one prior chemotherapy for palliative therapy~* Response Evaluation Criteria In Solid Tumors (RECIST) criteria for disease status assessment~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2~Exclusion Criteria:~* Concurrent administration of any other tumor therapy~* Pregnant or breast feeding~* Serious concomitant disorders~* Inability or unwillingness to take folic acid or vitamin B12 supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed (Type: EXPERIMENTAL): None
- Docetaxel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically- or cytologically- confirmed metastatic breast adenocarcinoma~* No HER2 overexpression or gene amplification~* No previous therapy for metastatic breast cancer is allowed~* Age 18-75 years~* At least 12 months interval since prior adjuvant therapy with taxanes and/or anthracyclines~* Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions)~* Performance status (WHO) 0-2~* Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the UNL in the presence of liver metastases)~* Adequate renal function (serum creatinine \<1.5 times the upper normal limit~* Adequate bone marrow function (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L)~* Written informed consent~Exclusion Criteria:~* Active infection~* Brain metastases~* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)~* History of stroke~* Anticoagulation therapy (except of low dose aspirin \<325mg)~* Other invasive malignancy except nonmelanoma skin cancer~* Psychiatric illness or social situation that would preclude study compliance~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bevacizumab-\>Epirubicin-\>Docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Nicotine Addiction in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 18yrs to 45yr old woman, read and write in English.~* Must smoke at least 5 or more cigarettes a day~* FTND score at least 4 or higher~* A CO reading of 10 or higher during screening~* Must be in good health as verified by medical history, screening exam, screen laboratory tests.~Exclusion Criteria:~* Excluded if using psychotropic medications, have contraindications to tolcapone use (e.g.. liver problems, allergy to tolcapone, history of no traumatic rhabdomyolysis or hyperpyrexia, confusion possibly related to medication), have other substance use disorder, are pregnant or breast feeding, have a current psychotic disorder, bipolar disorder, homicidal or suicidal ideation, have current (past month) substance use disorder, other than nicotine dependence, or are unable to fulfill the scheduled visits and procedures.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Tolcapone (Type: ACTIVE_COMPARATOR): 100mg tolcapone three times a day for 7 days then 100mg once a day on day 8
- Sugar Pill (Type: PLACEBO_COMPARATOR): Sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete